Colin Bristow

Stock Analyst at UBS

(0)
# 4725
Out of 5,298 analysts
94
Total ratings
23.68%
Success rate
-24.91%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
ABOS Acumen Pharmaceutica...
Maintains: Buy
6 4
0.99 304.04% 4 Mar 28, 2025
ENGN enGene Holdings
Downgrades: Neutral
34 7
4.49 55.9% 2 Feb 14, 2025
PFE Pfizer
Maintains: Neutral
29 28
24.3 15.23% 12 Feb 5, 2025
ALXO ALX Oncology Holding...
Maintains: Buy
4 3
0.54 307.41% 5 Jan 27, 2025
MRK Merck & Co
Maintains: Buy
125 120
86.39 38.9% 6 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
47 71
46.75 51.87% 3 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
70 96
112.39 -14.58% 3 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
562 586
484 21.07% 13 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
335 326
310.12 5.12% 7 Oct 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
130.65 54.61% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 41
15.77 159.99% 5 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 16
1.81 783.98% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
610.24 80.09% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
56 54
5.56 871.22% 2 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
58.59 185.03% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
788.89 -46.76% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
7.36 -72.83% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
0.71 2435.21% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
201.29 -27.47% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
57.69 30.01% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
1.38 1784.06% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
5.24 71.76% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021